Emergent Biosolutions Inc. (EBS) Receives “Positive” Rating from Wells Fargo & Co.
Emergent Biosolutions Inc. (NYSE:EBS)‘s stock had its “positive” rating reissued by stock analysts at Wells Fargo & Co. in a research note issued to investors on Friday.
Other equities analysts have also recently issued reports about the company. Singular Research reduced their price objective on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, June 28th. Cowen and Company restated a “hold” rating and set a $33.00 price objective on shares of Emergent Biosolutions in a research note on Sunday, August 7th. Zacks Investment Research upgraded Emergent Biosolutions from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. Finally, JPMorgan Chase & Co. reduced their price objective on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Emergent Biosolutions currently has an average rating of “Buy” and a consensus target price of $40.00.
Emergent Biosolutions (NYSE:EBS) traded up 12.97% during trading on Friday, hitting $31.36. 889,675 shares of the stock were exchanged. Emergent Biosolutions has a one year low of $26.12 and a one year high of $44.38. The stock’s 50 day moving average is $27.52 and its 200-day moving average is $34.11. The company has a market cap of $1.27 billion, a price-to-earnings ratio of 22.43 and a beta of 1.24.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. Emergent Biosolutions had a return on equity of 11.93% and a net margin of 11.61%. The firm had revenue of $101.49 million for the quarter, compared to the consensus estimate of $111.20 million. During the same quarter last year, the business earned $0.36 earnings per share. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, equities research analysts expect that Emergent Biosolutions will post $1.03 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. FIL Ltd bought a new stake in Emergent Biosolutions during the second quarter worth about $16,063,000. Mesirow Financial Investment Management Equity Management bought a new stake in Emergent Biosolutions during the second quarter worth about $15,439,000. Emerald Acquisition Ltd. bought a new stake in Emergent Biosolutions during the second quarter worth about $13,280,000. Vanguard Group Inc. boosted its stake in Emergent Biosolutions by 13.0% in the second quarter. Vanguard Group Inc. now owns 3,610,132 shares of the biopharmaceutical company’s stock worth $101,517,000 after buying an additional 415,470 shares during the last quarter. Finally, Numeric Investors LLC bought a new stake in Emergent Biosolutions during the second quarter worth about $10,765,000. Institutional investors own 89.95% of the company’s stock.
About Emergent Biosolutions
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.